A recent announcement from Moderna Inc. (MRNA) shows it will further increase its global vaccine production capacity of the Covid-19 vaccine. The company plans to distribute up to one billion doses this year as part of its production plan for 2021. 1.4 billion doses are projected to be manufactured in 2022.
Moderna will be able to make additional doses of their existing vaccine and are also able to produce a booster vaccine to treat mutations in the future.
FDA has already responded positively to Moderna’s request to include more doses per vaccine vial. This could take up to fifteen doses per vial; the company is looking into the matter. It is expected that Moderna will begin discussions with other regulators.
Meanwhile, Moderna Inc. (MRNA) released record sales of the COVID-19 vaccine in the fourth quarter of 2020. During the fourth quarter of 2020, its revenue spiked 4000%, from $ 14.1 million to $ 570.7 million. Based on the vaccine’s efficacy, the company began using the vaccine against COVID-19 in several countries, including the United States and Canada. In the fourth quarter of 2020, biotech incurred a $272 million net loss while achieving a loss of $123 million in last year’s fourth quarter.
For people over the age of 18, the Moderna Inc. (MRNA) vaccine has been approved by the United States Food and Drug Administration (FDA) for use. According to the company, enrollment in its late-stage vaccine study in adolescents 12 to 17 years of age has been completed, and testing in children six months to 11 years of age will begin shortly.